Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2026 Filed Mar 18, 2026 20:06 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000023 · wk-form4_1773864360.xml · derivative · entry 4 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,244 Underlying: Common Stock · 7,414 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:06 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Tax withholdingCommon Stock | 5,540 | $21.59 | $119,608.60 |
DisclosureSEC source: 0001438133-26-000023 · wk-form4_1773864360.xml · nonDerivative · entry 2 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,843 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:06 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 7,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000023 · wk-form4_1773864360.xml · nonDerivative · entry 1 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 20:27 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
SaleCommon Stock | 2 | $22.81 | $45.62 |
DisclosureSEC source: 0001438133-26-000022 · wk-form4_1773088030.xml · nonDerivative · entry 1 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,969 F1 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 4, 2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · derivative · entry 7 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,484 Underlying: Common Stock · 1,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · derivative · entry 6 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,503 Underlying: Common Stock · 1,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Tax withholdingCommon Stock | 647 | $18.95 | $12,260.65 |
DisclosureSEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · nonDerivative · entry 4 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,066 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionCommon Stock | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · nonDerivative · entry 3 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Tax withholdingCommon Stock | 887 | $18.95 | $16,808.65 |
DisclosureSEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · nonDerivative · entry 2 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 616 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Gasser Elizabeth AnneEVP, Chief Strategy Officer
|
Exercise / conversionCommon Stock | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000019 · wk-form4_1771537052.xml · nonDerivative · entry 1 Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · derivative · entry 7 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,478 Underlying: Common Stock · 1,495 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · derivative · entry 6 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,503 Underlying: Common Stock · 1,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Tax withholdingCommon Stock | 616 | $18.95 | $11,673.20 |
DisclosureSEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · nonDerivative · entry 4 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,411 F1 · shares: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 1,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · nonDerivative · entry 3 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Tax withholdingCommon Stock | 619 | $18.95 | $11,730.05 |
DisclosureSEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · nonDerivative · entry 2 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,532 F1 · shares: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Vosseller LeighEVP & CHIEF FINANCIAL OFFICER
|
Exercise / conversionCommon Stock | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000013 · wk-form4_1771536848.xml · nonDerivative · entry 1 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · derivative · entry 6 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,484 Underlying: Common Stock · 1,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · derivative · entry 5 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,503 Underlying: Common Stock · 1,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 372 | $18.95 | $7,049.40 |
DisclosureSEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · nonDerivative · entry 4 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,635 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · nonDerivative · entry 3 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Tax withholdingCommon Stock | 510 | $18.95 | $9,664.50 |
DisclosureSEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · nonDerivative · entry 2 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,910 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Morrison SusanEVP & Chief Admin. Officer
|
Exercise / conversionCommon Stock | 1,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000017 · wk-form4_1771537009.xml · nonDerivative · entry 1 Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · derivative · entry 6 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,487 Underlying: Common Stock · 897 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · derivative · entry 5 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,437 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 504 | $18.95 | $9,550.80 |
DisclosureSEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · nonDerivative · entry 4 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,274 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 897 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · nonDerivative · entry 3 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,778 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Carpenter RickChief Technology Officer
|
Tax withholdingCommon Stock | 808 | $18.95 | $15,311.60 |
DisclosureSEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · nonDerivative · entry 2 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,881 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:37 UTC |
Carpenter RickChief Technology Officer
|
Exercise / conversionCommon Stock | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000020 · wk-form4_1771537073.xml · nonDerivative · entry 1 Carpenter Rick · CIK 0001513889 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 77 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000016 · wk-form4_1771536990.xml · derivative · entry 3 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380 Underlying: Common Stock · 77 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Tax withholdingCommon Stock | 62 | $18.95 | $1,174.90 |
DisclosureSEC source: 0001438133-26-000016 · wk-form4_1771536990.xml · nonDerivative · entry 2 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,971 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:36 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionCommon Stock | 77 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000016 · wk-form4_1771536990.xml · nonDerivative · entry 1 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · derivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,911 Underlying: Common Stock · 5,983 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan, as amended. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,472 Underlying: Common Stock · 5,471 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 2,400 | $18.95 | $45,480.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,691 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 5,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Tax withholdingCommon Stock | 1,963 | $18.95 | $37,198.85 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,108 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:34 UTC |
Sheridan John FDirector · PRESIDENT & CEO
|
Exercise / conversionCommon Stock | 5,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000014 · wk-form4_1771536871.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · derivative · entry 10 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,484 Underlying: Common Stock · 1,097 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · derivative · entry 9 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,437 Underlying: Common Stock · 1,437 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 531 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · derivative · entry 8 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 531 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on February 15, 2022 pursuant to the Tandem Diabetes Care Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 2/15/2023, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 2/15/2023, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Tax withholdingCommon Stock | 452 | $18.95 | $8,565.40 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 6 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,276 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionCommon Stock | 1,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 5 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Tax withholdingCommon Stock | 592 | $18.95 | $11,218.40 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 4 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,631 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionCommon Stock | 1,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 3 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,223 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Tax withholdingCommon Stock | 219 | $18.95 | $4,150.05 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 2 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,786 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:33 UTC |
Hansen Shannon MarieEVP & Chief Legal Officer
|
Exercise / conversionCommon Stock | 531 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000012 · wk-form4_1771536816.xml · nonDerivative · entry 1 Hansen Shannon Marie · CIK 0001908267 · EVP & Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:09 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · derivative · entry 3 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,817 Underlying: Common Stock · 3,636 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on July 15, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 7/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:09 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Tax withholdingCommon Stock | 2,118 | $21.07 | $44,626.26 |
DisclosureSEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · nonDerivative · entry 2 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,062 F1 · kind: Shares withheld by Tandem Diabetes Care Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 21:09 UTC |
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
|
Exercise / conversionCommon Stock | 3,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-26-000003 · wk-form4_1768943392.xml · nonDerivative · entry 1 Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 21:02 UTC |
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000229 · wk-form4_1766005331.xml · derivative · entry 3 Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,658 Underlying: Common Stock · 7,415 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.